放射线治疗诊断剂市场－全球产业规模、份额、趋势、机会及预测（按放射性同位素、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球放射治疗诊断市场预计将从 2025 年的 111.5 亿美元大幅成长至 2031 年的 339.8 亿美元，复合年增长率为 20.41%。

诊断性放射治疗，主要应用于肿瘤学领域，是精准医疗的典范，它利用成对的放射性药物同时进行疾病的诊断和治疗。全球癌症发生率的不断攀升以及临床上对个人化治疗方法日益增长的需求，极大地推动了这个市场的发展。个人化治疗方案旨在最大限度地提高疗效，同时最大限度地降低全身毒性。这种双重方法使临床医生能够清楚地了解疾病的范围，并将放射治疗精准地输送到特定的细胞位置，从而促进了其在医疗保健系统中的广泛应用，最终改善患者的治疗效果。

然而，该产业在供应链稳定性方面面临严峻挑战，尤其是在医用放射性同位素的可靠供应方面。这些关键材料的生产严重依赖数量有限的老旧核子研究反应器，这使得市场极易受到计划外运作和物流中断的影响。根据欧洲核子医学协会预测，2024年底意外的核子反应炉维护问题将导致关键诊断用同位素发生器供应短缺高达40%，凸显了全球分销网络的脆弱性。

市场驱动因素

全球标靶化癌症发生率的上升是推动放射治疗诊断市场发展的主要因素。随着肿瘤疾病负担的加重，医疗机构优先考虑兼具诊断准确性和治疗效果的治疗性诊断方式，以应对复杂的病例。需要高阶治疗的病例数不断增加，也印证了对个人化治疗的需求。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告，预计2024年美国将新增2,001,140例癌症病例。日益增长的疾病负担直接推动了已通过核准的放射性配体疗法的商业性应用。诺华公司在2024年10月发布的《2024年第三季中期财务报告》中披露，其Pulvict疗法的季度净销售额为3.86亿美元，这凸显了市场对这类标靶治疗的巨大需求。

同时，公共和私人投资与资金筹措的激增正在改变该行业的竞争格局。大型製药企业意识到放射性药物的商业性可行性，正积极收购专业生物技术公司，以确保获得专有平台和生产基础设施。这些资金注入对于克服传统供应链的脆弱性以及加速新型同位素的开发至关重要。例如，百时美施贵宝在2024年2月的新闻稿中宣布，已完成对RaiseBio的收购，总对价约41亿美元。如此规模的资金注入标誌着产业正朝着扩大全球产能以满足预期长期需求的方向做出重大转变。

市场挑战

全球放射治疗诊断市场面临供应链脆弱性带来的重大挑战，尤其是关键医用放射性同位素的不稳定性。该行业依赖日益老化且产能下降的核子研究反应器来生产构成诊断和治疗药物基础的同位素。这些设施的非计划性停机或维修延误会立即造成瓶颈，阻碍救命放射性药物的生产。这种不可靠性迫使临床医生推迟或取消对时间要求严格的癌症治疗，削弱了人们对放射治疗诊断作为肿瘤学永续支柱的信心，并阻碍了医疗机构对必要基础设施的投资。

这些物流挑战的影响十分严重且可衡量。据美国核子医学与分子影像学会称，2024年计画外核子反应炉停驶将导致全球供不应求50%至100%，远低于正常需求。这些严重的供应中断直接限制了市场收入，并阻碍了同位素技术的普及，因为製药公司无法保证患者能够获得所需产品。因此，同位素供应的不稳定性仍然是限制该领域整体成长潜力的主要障碍。

市场趋势

全球放射治疗和诊断市场正经历一场意义重大的技术变革，其标誌是向标靶α粒子治疗（TAT）的转型。与常见的β发射同位素（如镏-177）不同，α发射体（如锕-225）能够释放短程、高线性能量转移（LET）的辐射，在保护周围健康组织的同时，还能高效地诱导双链DNA断裂，从而有效杀伤微转移灶。这种治疗方法方式的转变促使各大製药公司投入大量资金，以确保其专有的锕供应链和研发管线。例如，Astra Zeneca于2024年6月以约24亿美元收购了Fusion Pharmaceuticals公司，将其基于锕的放射性标记化合物整合到其肿瘤产品组合中。

同时，业内人士注意到，一些专门从事放射性药物CDMO（合约研发生产机构）的机构正在涌现，旨在缓解传统生产模式的脆弱性。为了应对超短半衰期同位素带来的物流复杂性，这些专业CDMO正在建构专门的基础设施，以实现分散式、即时生产，而非传统的集中式模式。这种结构性扩张对于确保商业性扩充性以及在核子反应炉停驶情况下的冗余备份至关重要。正如Nucleus RadioPharma在2024年5月的新闻稿中所宣布的那样，该公司宣布将新建两座面积超过10万平方英尺的设施，以解决全国范围内的供应链瓶颈问题。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球放射线治疗诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依放射性同位素（Technetium-99、镓-68、碘-131、碘-123、18F、Y-90、镏（Lu）177、铜（Cu）67、铜（Cu）64等）
  • 依应用领域（肿瘤科与非肿瘤科）
  • 依最终用户（医院/诊所、製药/生技公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美放射线治疗诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲放射线治疗诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区放射线治疗诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲放射线治疗诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲放射线治疗诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球放射线治疗诊断市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• TransCode Therapeutics, Inc
• Curium SAS
• GE Healthcare Inc
• Bayer AG
• Lantheus Medical Imaging, Inc
• Novartis AG
• Spectrum Pharmaceuticals, Inc
• Ipsen SA
• Actinium Pharmaceuticals, Inc
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Radiotheranostics Market is projected to expand significantly, growing from USD 11.15 Billion in 2025 to USD 33.98 Billion by 2031, representing a CAGR of 20.41%. Radiotheranostics represents a precision medical paradigm that employs paired radiopharmaceuticals to simultaneously diagnose and treat pathologies, primarily within the field of oncology. The market is largely driven by the rising global prevalence of cancer and a growing clinical preference for personalized therapeutic regimens that maximize efficacy while minimizing systemic toxicity. This dual approach enables clinicians to visualize the extent of disease and deliver targeted radiation to specific cellular sites, thereby encouraging widespread adoption across healthcare systems aimed at improving patient outcomes.

However, the sector encounters a substantial challenge regarding supply chain stability, particularly concerning the reliable availability of medical radioisotopes. The production of these essential materials relies heavily on a limited number of aging nuclear research reactors, leaving the market exposed to unscheduled outages and logistical disruptions. According to Nuclear Medicine Europe, unexpected reactor maintenance issues in late 2024 were projected to result in supply shortages of up to 40% for critical diagnostic isotope generators, underscoring the fragility of the global distribution network.

Market Driver

The rising global incidence of targetable cancers acts as the primary catalyst driving the radiotheranostics market. As the burden of oncological disease increases, healthcare providers are prioritizing theranostic modalities that combine diagnostic precision with therapeutic lethality to manage complex cases. This demand for personalized intervention is supported by the growing volume of diagnoses requiring advanced care; according to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, 2,001,140 new cancer cases were projected to occur in the United States in 2024. This intensifying disease burden has directly resulted in substantial commercial uptake for approved radioligand therapies, as evidenced by Novartis reporting in their October 2024 "Q3 2024 Interim Financial Report" that net sales for the therapy Pluvicto reached $386 million for the quarter, reflecting the critical market need for these targeted treatments.

Concurrently, a surge in public-private investments and funding is transforming the sector's competitive landscape. Acknowledging the commercial viability of radiopharmaceuticals, major pharmaceutical entities are aggressively acquiring specialized biotech firms to secure proprietary platforms and manufacturing infrastructure. These capital infusions are essential for overcoming historical supply chain fragilities and accelerating the development of novel isotopes. For instance, Bristol Myers Squibb announced in a February 2024 press release that it had finalized the acquisition of RayzeBio for a total equity value of approximately $4.1 billion. This level of financial commitment signals a definitive shift toward scaling global production capabilities to meet anticipated long-term demand.

Market Challenge

The Global Radiotheranostics Market contends with a critical impediment stemming from the fragility of its supply chain, specifically the inconsistent availability of essential medical radioisotopes. The industry relies on a shrinking number of aging nuclear research reactors to produce these isotopes, which form the foundation for paired diagnostic and therapeutic agents. Any unscheduled outage or maintenance delay at these facilities creates an immediate bottleneck, preventing the manufacturing of life-saving radiopharmaceuticals. This unreliability compels clinicians to postpone or cancel time-sensitive cancer treatments, thereby eroding confidence in radiotheranostics as a sustainable pillar of oncology and discouraging healthcare institutions from investing in necessary infrastructure.

The impact of these logistical failures is acute and measurable. According to the Society of Nuclear Medicine and Molecular Imaging, unexpected reactor downtime in 2024 resulted in supply shortages ranging from 50% to 100% of normal requirements across various global regions. These severe disruptions directly limit market revenue and stall adoption rates, as pharmaceutical companies cannot guarantee product delivery to patients. Consequently, the volatility of the isotope supply remains the primary friction point hindering the sector's overall growth potential.

Market Trends

The Global Radiotheranostics Market is undergoing a significant technical evolution defined by the transition toward Targeted Alpha-Particle Therapies (TATs). Unlike prevailing beta-emitting isotopes such as Lutetium-177, alpha-emitters like Actinium-225 deliver high linear energy transfer radiation over a short range, inducing double-strand DNA breaks that are highly effective against micro-metastases while sparing surrounding healthy tissue. This shift in therapeutic modality has triggered substantial investment from major pharmaceutical entities seeking to secure proprietary actinium supply chains and pipelines. For example, AstraZeneca finalized the acquisition of Fusion Pharmaceuticals in June 2024 for a transaction value of approximately $2.4 billion to integrate actinium-based radioconjugates into its oncology portfolio.

Simultaneously, the industry is observing the emergence of Radiopharmaceutical-Specialized CDMOs designed to mitigate historical manufacturing vulnerabilities. To address the logistical complexities associated with isotopes having ultra-short half-lives, these specialized Contract Development and Manufacturing Organizations are engineering purpose-built infrastructure capable of decentralized, just-in-time production, distinct from traditional centralized models. This structural expansion is crucial for ensuring commercial scalability and redundancy against reactor outages. As reported by Nucleus RadioPharma in a May 2024 press release, the organization announced the development of two new facilities totaling over 100,000 square feet to address nationwide supply chain constraints.

Key Market Players

• TransCode Therapeutics, Inc
• Curium SAS
• GE Healthcare Inc
• Bayer AG
• Lantheus Medical Imaging, Inc
• Novartis AG
• Spectrum Pharmaceuticals, Inc
• Ipsen S.A
• Actinium Pharmaceuticals, Inc
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc

Report Scope

In this report, the Global Radiotheranostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiotheranostics Market, By Radioisotope

• Technetium-99
• Gallium-68
• Iodine-131
• Iodine-123
• 18F
• Y-90
• Lutetium (Lu) 177
• Copper (Cu) 67
• Copper (Cu) 64
• Others

Radiotheranostics Market, By Application

• Oncology
• Non-Oncology

Radiotheranostics Market, By End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Radiotheranostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiotheranostics Market.

Available Customizations:

Global Radiotheranostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiotheranostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 5.2.2. By Application (Oncology v/s Non-Oncology)
  • 5.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Radiotheranostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Radioisotope
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Radiotheranostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Radioisotope
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Radiotheranostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Radioisotope
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Radiotheranostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Radioisotope
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Radiotheranostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Radioisotope
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Radiotheranostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Radioisotope
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Radiotheranostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Radioisotope
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Radiotheranostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Radioisotope
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Radiotheranostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Radioisotope
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Radiotheranostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Radioisotope
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Radiotheranostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Radioisotope
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Radiotheranostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Radioisotope
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Radiotheranostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Radioisotope
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Radiotheranostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Radioisotope
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Radiotheranostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Radioisotope
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Radiotheranostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Radioisotope
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Radiotheranostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Radioisotope
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Radiotheranostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Radioisotope
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Radiotheranostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Radioisotope
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Radiotheranostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Radioisotope
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Radiotheranostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Radioisotope
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Radiotheranostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Radioisotope
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Radiotheranostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Radioisotope
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Radiotheranostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Radioisotope
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Radiotheranostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. TransCode Therapeutics, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Curium SAS
• 15.3. GE Healthcare Inc
• 15.4. Bayer AG
• 15.5. Lantheus Medical Imaging, Inc
• 15.6. Novartis AG
• 15.7. Spectrum Pharmaceuticals, Inc
• 15.8. Ipsen S.A
• 15.9. Actinium Pharmaceuticals, Inc
• 15.10. Nordic Nanovector ASA
• 15.11. Y-mAbs Therapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer